Shares Babu Sharesss

[Gachibowli_Diwakar]

[quote name='k2s' timestamp='1320258999' post='3057623']
[/b]

aa fafa rate antha cheap aa ?????
[/quote]

[img]http://www.imageping.com/out.php/i11964_Brahmi4.gif[/img]

[Vikkas]

2 hours bayata kellesariki chaala maripoyayi shares [img]http://www.imageping.com/out.php/i11964_Brahmi4.gif[/img]

[Gachibowli_Diwakar]

[quote name='Vikkas' timestamp='1320259775' post='3057710']
2 hours bayata kellesariki chaala maripoyayi shares [img]http://www.imageping.com/out.php/i11964_Brahmi4.gif[/img]
[/quote]

EXEL shares midha ni opinions cheppu bhayya .. kondhaam anukuntunna

[k2s]

[quote name='Little Star' timestamp='1320259315' post='3057670']
ee Ftimers ahankaaram dhourjanyam nasinchaali...
[/quote]

[img]http://www.desigifs.com/sites/default/files/brahmam_style18_0.gif?1290369075[/img] me contractors ki FTs ante eppudu chulakaney [img]http://www.desigifs.com/sites/default/files/brahmam_style18_0.gif?1290369075[/img]

[littlestar]

[quote name='Vikkas' timestamp='1320259775' post='3057710']
2 hours bayata kellesariki chaala maripoyayi shares [img]http://www.imageping.com/out.php/i11964_Brahmi4.gif[/img]
[/quote]
DB Warren Buffet vi..2 hrs lite theeskuntene Market shake aipothundi

[k2s]

[quote name='dennis' timestamp='1320259047' post='3057633']

Hai uncle....how r u?
[/quote]

as usual [img]http://i48.tinypic.com/m7u7wx.gif[/img]

[k2s]

[quote name='Silence..Please' timestamp='1320259451' post='3057681']

[img]http://www.imageping.com/out.php/i11964_Brahmi4.gif[/img]
[/quote]
[img]http://www.imageping.com/out.php/i23956_BR24.gif[/img]

[Vikkas]

[quote name='Silence..Please' timestamp='1320259957' post='3057730']

EXEL shares midha ni opinions cheppu bhayya .. kondhaam anukuntunna
[/quote]

ninna 40% padindi. enduku?

[littlestar]

[quote name='k2s' timestamp='1320260017' post='3057737']

[img]http://www.desigifs.com/sites/default/files/brahmam_style18_0.gif?1290369075[/img] me contractors ki FTs ante eppudu chulakaney [img]http://www.desigifs.com/sites/default/files/brahmam_style18_0.gif?1290369075[/img]
[/quote]

Dialogue reverse la chepthunnav endi..India nudni evadanna ekkada US lo ani adigithe oka place cheppaleni situation vayya naadi..adiginodu malli next month lo adigi...nenu inkoka place chepthunte muddha digatle bhayya D:

[Gachibowli_Diwakar]

[quote name='Vikkas' timestamp='1320260155' post='3057748']

ninna 40% padindi. enduku?
[/quote]

malli peruguthundhemo ani

[k2s]

[quote name='Little Star' timestamp='1320260164' post='3057749']

Dialogue reverse la chepthunnav endi..India nudni evadanna ekkada US lo ani adigithe oka place cheppaleni situation vayya naadi..adiginodu malli next month lo adigi...nenu inkoka place chepthunte muddha digatle bhayya D:
[/quote]

spoon tho thinu bhayya

[littlestar]

[quote name='k2s' timestamp='1320260534' post='3057778']

spoon tho thinu bhayya
[/quote]
spoon ni thinu annattundi

[Vikkas]

[quote name='Silence..Please' timestamp='1320260263' post='3057761']

malli peruguthundhemo ani
[/quote]

naa question nuvvu enduku kontunav ani kaadhu baaa.
ninna 40% padataniki reason emiti?

[Gachibowli_Diwakar]

[quote name='Vikkas' timestamp='1320260918' post='3057808']

naa question nuvvu enduku kontunav ani kaadhu baaa.
ninna 40% padataniki reason emiti?
[/quote]

Exelixis' EXEL clinical development program for lead drug cabozantinib hit a setback Monday after the firm announced that the Food and Drug Administration failed to grant a Special Protocol Assessment for its pivotal clinical trial. We believe the firm's inability to gain the FDA's endorsement for its trial design increases the riskiness of its clinical program for cabozantinib in patients with metastatic castrate-resistant prostate cancer, and we're lowering our fair value estimate after slightly decreasing our assigned probability of approval

[Vikkas]

[quote name='Silence..Please' timestamp='1320261077' post='3057820']

Exelixis' EXEL clinical development program for lead drug cabozantinib hit a setback Monday after the firm announced that the Food and Drug Administration failed to grant a Special Protocol Assessment for its pivotal clinical trial. We believe the firm's inability to gain the FDA's endorsement for its trial design increases the riskiness of its clinical program for cabozantinib in patients with metastatic castrate-resistant prostate cancer, and we're lowering our fair value estimate after slightly decreasing our assigned probability of approval
[/quote]
last 8 months nunchi paduthuney undhi kada bhayya.
madhya madhyalo small spikes vasthunayi paiki.
intrest unte konu, ekkuva rojulu hold cheyyadam mathram risk